Acetylcholinesterase inhibition of Alzheimer's disease

Current Pharmaceutical Design

Volumn 10, Issue 3, 2004, Pages 231-251

  Ibach, Bernd ^a   Haen, Ekkehard ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID; ANALGESIC AGENT; ANTACID AGENT; ANTIANGINA PECTORIS AGENT; ANTIDIABETIC AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CIMETIDINE; DIAZEPAM; DIGOXIN; DONEPEZIL; ERYTHROMYCIN; FLUOXETINE; GALANTAMINE; KETOCONAZOLE; NEOSTIGMINE; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PHYSOSTIGMINE; PLACEBO; PYRIDOSTIGMINE; RIVASTIGMINE; TACRINE; UNINDEXED DRUG; WARFARIN;

AGING; ALZHEIMER DISEASE; ANOREXIA; ATTENTION; BRADYCARDIA; CELL LOSS; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; CONFUSION; DEMENTIA; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; ENZYME INHIBITION; FATIGUE; FOREBRAIN; GASTROINTESTINAL SYMPTOM; HISTORY; HUMAN; INDUSTRIALIZATION; INSOMNIA; LIMBIC SYSTEM; LIVER TOXICITY; MENTAL DETERIORATION; MENTAL FUNCTION; MUSCLE CRAMP; NAUSEA; NEOCORTEX; NERVE CELL; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SENILE PLAQUE; SYNAPSE; VOMITING;

ALZHEIMER DISEASE; CARBAMATES; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; GALANTAMINE; HUMANS; INDANS; PHENYLCARBAMATES; PIPERIDINES; TACRINE;

EID: 0346656610     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043386509     Document Type: Review

References (134)

1. Karczmar AG. Intern Encyclop Pharmacol Therap Pergamon Press: Oxford 1970.
2. Jobst J, Hesse O. Ann Chem Pharm 1864; 129: 115.
3. Christie A. Sad Cypress published by William Collins Sons and Company Limited 1933.
4. Karczmar A. Neurochem Int 1998; 32(5-6): 401-11.
5. Carlock L, Chen WL, et al. Cholinesterase Risk Asssessment Work Group(ACRA), Washington D. D1-126.
6. Peters BH.: Levin HS. Ann Neurol 1979; 6(3): 219.
7. Davis KL, Mohs RC, Tinklenberg JR. N Engl J Med 1979; 301(17): 946
8. Thal LJ, Fuld PA, Masur DM, Sharpless NS, Davies P. Psychopharmacol Bull 1983; 19(3): 454.
9. Giacobini EAlzheimer's disease: From Molecular Biology to Therapy Quinn D, Balasubramaniam AS, Doctor BP, Taylor P. (Eds): Birkhäuser: Boston pp. 187-204.
10. Bowen DM, Smith CB, White P, Davison AN. Brain 1976; 99(3): 459.
11. Davies P, Maloney AJ. Lancet 1976; 2(8000): 1403.
12. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE. J Neurol Sci 1977; 34(2): 247.
13. Koelle GB. In Handbuch d exper Pharmakol Koelle GB(Ed): 1963 Springer-Verlag Berlin pp287-298.
14. Mesulam MM. In Cholinergic Mechanisms, From Molecular Biology to Clinical Significance Klein J, Löffelholz K. (eds): Elseviewer: Amsterdam pp. 285-297.
15. Karczmar AG. Neuropsychopharmacol 9: 181-199.
16. Drachman DA. Leavitt J Arch Neurol 1974; 30(2): 113
17. Burns A, Whitehouse P, Arendt T, Forsti H. Science 1982; 215: 1237.
18. Nilsson L, Nordberg A, Hardy J, Wester P, Winblad B. J Neural Transm 1986; 67(3-4): 275.
19. Rylett RJ, Ball MJ, Colhoun EH. Brain Res 1983; 19: 289(1-2): 169.
20. Kish SJ, Robitaille Y, El-Awar MDeck JH, Simmons J, Schut L, Chang LJ, et al. Ann Neurol 1989; 26(3): 362.
21. Procter AW, Palmer AM, Francis PT, Lowe SL, Neary D, Murphy E, et al. J Neurochem 1988; 50(3): 790.
22. Lowe SL, Bowen DM, Francis PT, Neary D. Neuroscience 1990; 38(3): 571.
23. Hyman BT, Van Hoesen GW, Damasio AR. Ann Neurol 1987; 22(1):37.
24. Francis PT, Sims NR, Procter AW, Bowen DM. J Neurochem 1993; 60(5): 1589Review.
25. Rossor MN, Garrett NJ, Johnson AL, Mountjoy CQ, Roth M, Iversen LL. Brain 1982; 105(Pt 2): 313.
26. Francis PT, Bowen DM, Lowe SL, Neary D, Mann DM, Snowden JS. J Neurol Sci 1987; 78(1): 1.
27. Rossor M, Iversen LL. Br Med Bull 1986; 42(1): 70.
28. Kar S, Issa AM, Seto D, Auld DS, Collier B, Quirion R. J Neurochem 1998; 70(5): 21797.
29. Auld DS, Kar S, Quirion R. Trends Neurosci 1998; 21(1): 43.
30. Francis PT, Palmer AM, Snape M, Wilcock GK. J Neurol Neurosurg Psychiatry 1999; 66,(2): 137.
31. Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM, et al. Curr Biol 1994; 14(12): 1077.
32. Nitsch RM. Neurodegeneration 1996; 5(4): 477.
33. Karczmar AG. In SDAT models and their dynamics Becker R, Giacobini E. Eds Birkhäuser: Boston 1991; pp. 141-152.
34. Hanin I. Life Sci 1996; 58(22): 1955.
35. Woodruff-Pak DS, Vogel RW, 3rd Wenk GL. Proc Natl Acad Sci USA 200 1; 98(4): 2089.
36. Karczmar AG. Neuropsychopharmacology 1993; 9(3): 181.
37. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling, N. N Engl J Med 1986; 315(20): 1241.
38. Sugimoto H, Iimura Y, Yamanishi Y, et al. Bioorg Med Chem Lett 1992; 2(8): 871.
39. Fink DM, Bores GM, Effland RC, Huger FP, Kurys BE, Rush DK, et al. J Med Chem 1995; 38(18): 3645.
40. Kojima J, Nakajima K, Ochiai M, Nakayama K. Methods Find Exp Clin Pharmacol 1997; 19(4): 245.
41. Mimori Y, Nakamura S, Yukawa M. Bebav Brain Res 1997; 83(1-2):25.
42. Rogers SL, Friedhoff LT. Dementia 1996; 7(6): 293.
43. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Arch Intern Med 1998; 158(9): 1021.
44. Rogers SL, Farlow MR, Doody RS, Mobs R, Friedhoff LT. Neurology 1998; 50(1): 136.
45. Zhu XD, Cuadra G, Brufani M, Maggi T, Pagella PG, Williams E, et al. J Neurosi Res 1996; 43(1): 120.
46. Snape MF, Anderson SMP, Misra A. Br J Pharmacol 1996; 117: 163
47. Rogers SL, Friedhoff LT. Br J Clin Pharmacol 1998; 46 Suppl 1: 1.
48. Mihara M, Ohnishi A, Tomono Y, Hasegawa J, Shimamura Y, Yamazaki K, et al. Int J Clin Pharmacol Ther Toxicol 1993; 31(5): 223.
49. Aricept Product monography EISAI/ Pfizer 1999.
50. Ohnishi A, Mihara M, Kamakura H, Tomono Y, Hasegawa J, Yamazaki K, et al. J Clin Pharmacol 1993; 33(11): 1086.
51. Tiseo PJ, Perdomo CA, Friedhoff LT. Br J Clin Pharmacol 1998; 46 Suppl 1: 19.
52. Tiseo PJ, Rogers SL, Friedhoff LT. Br J Clin Pharmacol 1998; 46 Suppl 1: 13.
53. Tiseo PJ, Foley K, Friedhoff LT. Br J Clin Pharmacol 1998; 46 Suppl 1: 56.
54. Tiseo PJ, Vargas R, Perdomo CA, Friedhoff LT. Br J Clin Pharmacol 1998; 46 Suppl 1: 51.
55. Tiseo PJ, Perdomo CA, Friedhoff LT. Br J Clin Pharmacol 1998; 46 Suppl 1: 30.
56. Tiseo PJ, Perdomo CA, Friedhoff LT. Br J Clin Pharmacol 1998; 46 Suppl 1: 25.
57. Tiseo PJ, Perdomo CA, Friedhoff LT. Br J Clin Pharmacol 1998; 46 Suppl 1: 40.
58. Tiseo PJ, Perdomo CA, Friedhoff LT. Br J Clin Pharmacol 1998; 46 Suppl 1: 35.
59. Tiseo PJ, Perdomo CA, Friedhoff LT. Br J Clin Pharmacol 1998; 46 Suppl 1: 45.
60. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, et al. Dement Geriatr Cogn Disord 1999; 10(3): 237.
61. Rogers SL, Friedhoff LT. Eur Neuropsycho-pharmacol 1998; 8(1): 67.
62. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al. Neurology 2001; 57(3): 489.
63. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al. Neurology 2001; 57(3): 481.
64. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. Neurology 2001; 57(4): 613.
65. Pratt RD, Geldmacher D, Peromo CA. (abstract): Neurology 1999 52 Suppl 2: 481.
66. Rosen WG, Mobs RC, Davis KL. Am J Psychiatry 1984; 141(11): 1356.
67. Guy W. ECDEU Assessment Manual for Psychopharmaco-logy National Institute of Mental Health: Rockville 1979; Publication number 76-388.
68. Folstein MF, Folstein SE, McHugh PR. J Psychiatr Res 1975; 12(3):189.
69. Wood S, Cummings IL. Dis Manage Health Outcome 1999; 5, 1.
70. Berg L, Miller JP, Baty J, Rubin EH, Morris JC, Figiel G. Ann Neurol 1992; 31(3): 242.
71. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. Alzheimer Dis Assoc Disord 1997; 11 Suppl 2: 33.
72. Homma A, Takeda M, Imai Y, Udaka F, Hasegawa K, Kameyama M, et al. Dement Geriatr Cogn Disord 2000; 11(6): 299.
73. Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Neurology 2001; 57(3): 467.
74. Fabbrini G, Barbanti P, Bonifati V, Colosimo C, Gasparini M, Vanacore N, et al. Acta Neurol Scand 2001; 103(2): 123.
75. Moraes-Cerdeira RM, Burandt Jr CL, Bastos JK, Nanayakkara D, Mikell J, Thurn J, et al. Planta Med 1997; 63(5): 472.
76. Moraes-Cerdeira RM, Bastos JK, Burandt Jr CL. Planta Med 1997; 62(5): 93.
77. Viladomat F, Bastida J, Codina C. Journal of Natural Products 1992; 55(6): 804.
78. Bastida J, Viladomat F, Llabres JM. Planta Med 1990; 56(1): 123.
79. Proskurnina NF, Yakovleva A.P. Journal of General Chemistry of the USSR 1952; 2(10): 1941.
80. Szewczyk J, Wilson JW, Lewin AH. J Heterocyclic Chem 1995; 32(1):195.
81. Czollner L, Frantsits W, Küenburg B. Tetrahedron Lett 1998; 39(15): 2087.
82. Kovanev VA, Khmelevskii IM, Ganina SS. Eksp Khir Anesteziol 1967; 12(4): 65
83. Gujral VV. Indian Pediatr 1965; 2(3): 89.
84. Gopel W. Psychiatr Neurol Med Psychol (Leipz) 1971; 23(12): 712.
85. Thomsen T, Kaden B, Fischer JP, Bickel U, Barz H, Gusztony G, et al. Eur J Clin Chem Clin Biochem 1991; 29(8): 487.
86. Thomsen T, Kewitz H. Life Sci 1990; 46(21): 1553.
87. Thomsen T, Zendeh B, Fischer JP, Kewitz H. Biochem Pharmacol 1991; 41(1): 139.
88. Thomsen T, Bickel U, Fischer JP, Kewitz H. Eur J Clin Pharmacol 1990; 39(6): 603.
89. Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL, FEBS Lett 1999; 463(3): 321.
90. Maelicke A, Albuquerque EX, Eur J Pharmacol 2000; 393(1-3): 165.
91. Janssen Reminyl tablets prescribing information Janssen Pharmaceutica NV 2000.
92. Bickel U, Thomsen T, Fischer JP, Weber W, Kewitz H. Neuropharmacology 1991; 30(5): 447.
93. Bachus R, Bickel U, Thomsen T, Roots I, Kewitz H. Pharmacogenetics 1999; 9(6): 661.
94. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. Neurology 2000; 54(12): 2269.
95. Raskind MA, Peskind ER, Wessel T, Yuan W. Neurology 2000; 54(12):2261.
96. Wilcock G, Lilienfeld S, Gaens E. BMJ 2000; 321(7274): 1445.
97. Wilcock G, Lilienfeld S, Seventh World Alzheimer Congress: 2000; Washington DC.
98. Wilkinson D, Lilienfeld S, Truyen L. Springfield Symposium on Advances in Alzheimer Therapy 2000; Stockholm.
99. Enz A, Boddeke H, Gray J, Spiegel R. Ann NY Acad Sci 1991; 640: 272.
100. Weinstock M, Razin M, Chorev M, Enz A. J Neural Transm Suppl 1994;43:219.
101. Enz A, Floersheim P. In Cholinesterase inhibitors: an overview of their mechanisms of actionIn Alzheimer disease: from molecular biology to therapy Becker R, Giacobini EEdsBirkhäuser: Boston 1996; pp. 211-5.
102. Cutler NR, Polinsky RJ, Sramek JJ, Enz A, Jhee SS, Mancione L, et al. Acta Neurol Scand 1998; 97(4): 244.
103. Jann MW. Pharmacotherapy 2000; 20(1): 1.
104. Polinsky RJ. Clinical Therapeutics 20(4): 1998.
105. Spencer CM, Noble S. Drugs Aging 1998; 13(5): 391.
106. Anand R, Hartman D, Hayes P. In Alzheimer disease: from molecular biology to therapy Becker R, Giacobini E. (Eds.): Birkhäuser: Boston 1996; 239.
107. Anand R, Gharabawi G, Enz A. J Drug Dev Clin Pract 1996.
108. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. BMJ 1999; 318(7184): 633.
109. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Lancet 2000; 3 56(9247): 2031.
110. Wilkinson D, Passmore P, Potocnik F, Maud C, Hock C. 2000; ECNP.
111. Kwak Y, Han IW, Baik J, Koo MS. Lancet 2000; 355(9222): 2222.
112. Corey-Bloom J, Anand R, Veach J. Int J Geriatr Psychopharmacol 1998; 1: 55.
113. Farlow M, Anand R, Messina J Jr., Hartman R, Veach J. Eur Neurol 2000; 44(4): 236.
114. Rösler M, Retz W, Retz-Junginger P, Dennler J. Behavioural Neurology 1998/1999; 11: 211.
115. Kumar V, Anand R, Messina J, Hartman R, Veach J. Eur J Neurol 2000; 7(2): 159.
116. Corrrection for Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. BMJ 318(7184): 633; BMJ 2001; 322: 1456.
117. Dooley M, Lamb HM. Drugs Aging 2000; 16(3): 199-226 Original Data in Japanese.
118. McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D, Stevens T, et al, Int J Geriatr Psychiatry 2000; 15(5): 387.
119. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. Neurology 1994; 44(12): 2308.
120. Fahn S, Elton RL. In Recent developments in Parkinson's disease. Members of the UPDRS development committee: unified Parkinson's disease rating scale. Fahn S, Mardsen CD, Calne DB, Goldstein M. Eds. MacMillan Healthcare Information: Florham Park NJ 1987; 153.
121. Gottfries CG, Brane G, Gullberg B, Steen G. Arch Gerontol Geriatr 1982; 1(4):311.
122. DeJong R, Osterlund OW, Roy GW. Clin Ther 1989; 11(4): 545.
123. Reisberg B, Ferris SH, de Leon MJ, Crook T. Am J Psychiatry 1982; 139(9):1136.
124. Lawton MP, Brody EM. Gerontologist 1969; 9(3): 179.
125. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Am J Occup Ther 1999; 53(5): 471.
126. Buysse DJ, Reynolds CF3rd, Monk TH, Berman SR, Kupfer DJ. Psychiatry Res 1989; 28(2): 193.
127. Teunisse S, Derix M, Mvan Crevel H. Arch Neurol 1991; 48(3): 274.
128. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Ann Neurol 1980; 7(5): 486.
129. Blau TH. Prof Psychol 1977; 8: 464.
130. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. Alzhemier Dis Assoc Disord 1997; 11 Suppl. 2: 33.
131. Schmeidler J, Mohs RC, Aryan M. Alzhemier Dis Assoc Disord 1998; 12(3): 146.
132. Danysz W, Parsons CG, Jirgensons A, Kauss V, Tillner J. Aminoalkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists. Curr Pharm Design 2002; 8(10): 835-43.
133. Halldin C, Gulyas B, Farde L. PET studies with carbon-11 radioligands in neuropsychopharmacological drug development. Curr Pharm Design 2001; 7(18): 1907-29.
134. Schechter LE, Dawson LA, Harder JA. The potential utility of 5-HT1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer s disease. Curr Pharm Design 2002; 8(2): 139-45.